After two and a half years providing COVID-19 testing services to New England and beyond – including over 1.6 million tests – JAX’s Clinical Genomics Laboratory has suspended COVID-19 testing as of Friday, July 29, 2022, in alignment with the significant decrease in COVID-19 PCR testing demand. We will continue to monitor the pandemic and testing needs, and are prepared to reinstate testing services should demand increase. We are grateful to our community partners for supporting and collaborating with the JAX CLIA lab on this important endeavor.
While testing and sequencing services are no longer JAX’s focus at present, we are continuing our vital COVID-19 research, including the investigating the biological complexities of COVID, long COVID, and developing mouse models for the study of this virus.
The JAX CLIA lab’s focus has now returned to serving the oncology community with complex tumor profiling assays that help cancer patients and their physicians learn about specific tumors and provide insight into the most promising treatment options. We are proud of the continued role we play in improving human health and empowering the global biomedical community in our shared quest to improve human health.
Recent News from JAX
-
Press Release
December 02, 2020
JAX nominated as a healthcare hero
The Hartford Business Journal has recognized JAX among its 2020 Health Care Heroes in the Innovation category, recognizing an organization that has made a positive advancement in medical care or medical science.
-
Search Magazine
May 19, 2020
Help for heroes
Coronavirus testing at The Jackson Laboratory helps officials track and prevent transmission of COVID-19. To date, JAX has processed more than one million tests.
-
Research HighlightAugust 18, 2023Explaining long COVID and symptoms of prolonged inflammation
A new study by Weill Cornell Medicine and JAX could help explain symptoms of prolonged inflammation and long COVID in people who have had the disease. -
Research HighlightJanuary 26, 2023Examining long COVID
New JAX research is examining long COVID using data from healthcare systems across the US as part of the National COVID Cohort Collaborative (N3C). -
Research HighlightAugust 18, 2022Defining long COVID with patient data
Peter Robinson is working with hospital systems across the U.S. to pool COVID patient data and better define the scope of the long COVID problem and provide better clinical insight for patients. -
Featured ArticleNovember 03, 2021Examining the Delta COVID-19 variant and more
What is the status of the SARS-CoV-2 variant Delta now? What other variants might emerge? And when can we finally move forward into the "new normal?"
-
Research HighlightJuly 26, 2023Genetically diverse mice model the variable human response to SARS-CoV-2
JAX researchers have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection. This will allow scientists to model patient variation in COVID-19 outcome. -
Research HighlightNovember 10, 2022Arming the immune system against SARS-Cov-2
Derya Unutmaz and his team have capitalized on cancer immunotherapy techniques to develop potential variant-proof treatments for COVID-19. -
Tech CornerJanuary 14, 2022The challenge of Omicron: exploring the new variant
With the arrival of the Omicron COVID-19 variant, we take the time to examine how it got here and what the future holds for this and other variants. -
Research HighlightSeptember 22, 2021JAX is tracking sub-genomic SARS-CoV-2 variation
Chia-Lin Wei looked at SARS-CoV-2 RNA genomes and sub-genomic viral RNA in symptomatic and asymptomatic patients and found distinct, consistent differences between the patient groups. The findings have important implications for developing better COVID-19 risk mitigation and clinical strategies.